![conference banner](/images/conference-banner.jpeg)
Abstract
Chalcones (1,3-diphenylpropen-1-ones) are naturally occurring compounds belonging to the flavonoid family and are largely investigated in various therapeutic area and especially as antitumor drugs. In the latter field, the literature survey indicates that effect on the cell cycle is one of the most important targets domains of chalcones. In this review, we will shed light on: a) the structural criteria responsible for the cell cycle perturbations, b) the activity of chalcones on cell cycle molecular players or regulators c) the correlation between the chalcone-structure and proteins involved directly or not in cell cycle regulation and apoptosis by enhancement of proapoptotic molecules expression. We will discuss some perspectives related on how can we deal with chemical modification of chalcones to come up with more potent compounds to provide new ways for cancer treatment.
Keywords: Chalcones, 1,3-diphenylpropenones, cell cycle, cancer
Current Drug Targets
Title: Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?
Volume: 10 Issue: 4
Author(s): Boumendjel Ahcene, Ronot Xavier, Boutonnat Jean, Ahcene Boumendjel, Xavier Ronot and Jean Boutonnat
Affiliation:
Keywords: Chalcones, 1,3-diphenylpropenones, cell cycle, cancer
Abstract: Chalcones (1,3-diphenylpropen-1-ones) are naturally occurring compounds belonging to the flavonoid family and are largely investigated in various therapeutic area and especially as antitumor drugs. In the latter field, the literature survey indicates that effect on the cell cycle is one of the most important targets domains of chalcones. In this review, we will shed light on: a) the structural criteria responsible for the cell cycle perturbations, b) the activity of chalcones on cell cycle molecular players or regulators c) the correlation between the chalcone-structure and proteins involved directly or not in cell cycle regulation and apoptosis by enhancement of proapoptotic molecules expression. We will discuss some perspectives related on how can we deal with chemical modification of chalcones to come up with more potent compounds to provide new ways for cancer treatment.
Export Options
About this article
Cite this article as:
Ahcene Boumendjel, Xavier Ronot, Jean Boutonnat, Boumendjel Ahcene, Ronot Xavier and Boutonnat Jean, Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846416
DOI https://dx.doi.org/10.2174/138945009787846416 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
Current Pharmaceutical Design Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science The Integrative Network of Gene Expression, MicroRNA, Methylation and Copy Number Variation in Colon and Rectal Cancer
Current Bioinformatics E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry In Silico and Biochemical Analyses Identify Quinone Reductase 2 as a Target of Piceatannol
Current Medicinal Chemistry Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research An Intimate Alliance of DNA-Damage Response Network with Cell-Cycle Checkpoints Amid Events of Uncontrolled Cellular Proliferation: A Mini- Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway
Clinical Cancer Drugs Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Editorial [Hot Topic: Hydrolase Versus Other Functions of Members of the Alpha/Beta-Hydrolase Fold Superfamily of Proteins (Guest Editor: Pascale Marchot and Arnaud Chatonnet)]
Protein & Peptide Letters NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design